2017 Fiscal Year Final Research Report
Enhanced antitumor efficacy of oncolytic HSV1, G47delta
| Project/Area Number |
15K10328
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Tanaka Minoru 東京大学, 医科学研究所, 特任准教授 (50332581)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
稲生 靖 東京大学, 医科学研究所, 准教授 (50372371)
藤堂 具紀 東京大学, 医科学研究所, 教授 (80272566)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | ウイルス療法 / がん治療用ウイルス / 口唇ヘルペス / G47Δ / 抗腫瘍免疫 |
|---|
| Outline of Final Research Achievements |
The viral therapy is a new treatment of enhanced tumor-selective viral replication and cell killing. G47Δ is a third-generation oncolytic herpes simplex virus type 1 (HSV-1) that has triple mutations created in the HSV-1 genome. G47Δ can actually induce systemic antitumor immunity by activating natural killer cells and Th1 cells. We believe G47Δ will become a standard treatment for malignant tumors.
|
| Free Research Field |
悪性脳腫瘍
|
